Cytokinetics hopes to resurrect omecamtiv

Remember omecamtiv mecarbil? It might be back. The Cytokinetics heart failure project, whose technically successful Galactic-HF study was nevertheless bad enough for Amgen to pull the plug on a licensing deal, could soon be reviewed by the FDA.